381 A phase I study of BAY 43-90006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced solid tumors
A. Awada, A. Hendlisz, T. Gil, B. Schwartz, S. Bartholomeus, E. Brendel, D. de Valeriola, C. Haase, T. Delaunoit, M. PiccartVolume:
2
Year:
2004
Language:
english
DOI:
10.1016/s1359-6349(04)80388-4
File:
PDF, 147 KB
english, 2004